User:Raia Hasan/Sandbox 1
From Proteopedia
| Line 54: | Line 54: | ||
| - | How Botox is being used to treat Sialorrhea? Sialorrhea is producing excessive saliva or drooling involuntarily. This problem is mostly found in neurologically affected children such as cerebral palsy patients and in adults who have been diagnosed with Parkinson's disease. In some cases, excessive salivation may be present in patients who have had a stroke. This is most commonly caused by an inability to have full control of the oral and facial muscles. Botox is injected into the salivary glands to temporarily decrease saliva output. | + | How Botox is being used to treat Sialorrhea? Sialorrhea is producing excessive saliva or drooling involuntarily. This problem is mostly found in neurologically affected children such as cerebral palsy patients and in adults who have been diagnosed with Parkinson's disease. In some cases, excessive salivation may be present in patients who have had a stroke. This is most commonly caused by an inability to have full control of the oral and facial muscles. Botox is injected into the salivary glands to temporarily decrease saliva output. <ref name=sia>Oliveira, Ademar Francisco de Filho et al. “Application of botulinum toxin to treat sialorrhea in amyotrophic lateral sclerosis patients: a literature review.” Einstein (Sao Paulo, Brazil) vol. 14,3 (2016): 431-434. doi:10.1590/S1679-45082016RB3594</ref> |
| Line 80: | Line 80: | ||
<ref name=prot>Patil S, Willett O, Thompkins T, Hermann R, Ramanathan S, Cornett EM, Fox CJ, Kaye AD. Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States. Curr Pain Headache Rep. 2016 Mar;20(3)http://dx.doi.org/10.1007/s11916-016-0545-0</ref> | <ref name=prot>Patil S, Willett O, Thompkins T, Hermann R, Ramanathan S, Cornett EM, Fox CJ, Kaye AD. Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States. Curr Pain Headache Rep. 2016 Mar;20(3)http://dx.doi.org/10.1007/s11916-016-0545-0</ref> | ||
<ref name=mayo>Mayo Foundation for Medical Education and Research. (2021, September 3). Cervical dystonia. Mayo Clinic. Retrieved April 27, 2022, from https://www.mayoclinic.org/diseases-conditions/cervical-dystonia/symptoms-causes/syc-20354123</ref> | <ref name=mayo>Mayo Foundation for Medical Education and Research. (2021, September 3). Cervical dystonia. Mayo Clinic. Retrieved April 27, 2022, from https://www.mayoclinic.org/diseases-conditions/cervical-dystonia/symptoms-causes/syc-20354123</ref> | ||
| - | + | <ref name=A>Naumann M, Jankovic J: Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004 Jul;20(7):981-90. doi: 10.1185/030079904125003962. [Article]</ref> | |
| - | + | <ref name=sia>Oliveira, Ademar Francisco de Filho et al. “Application of botulinum toxin to treat sialorrhea in amyotrophic lateral sclerosis patients: a literature review.” Einstein (Sao Paulo, Brazil) vol. 14,3 (2016): 431-434. doi:10.1590/S1679-45082016RB3594</ref> | |
| - | + | ||
| - | + | ||
<ref name=allergen>PMID: 26706467</ref>Pellett, S., Tepp, W. H., Scherf, J. M., Pier, C. L., & Johnson, E. A. (2015). Activity of botulinum neurotoxin type D (strain 1873) in human neurons. Toxicon : official journal of the International Society on Toxinology, 101, 63–69. https://doi.org/10.1016/j.toxicon.2015.04.015 | <ref name=allergen>PMID: 26706467</ref>Pellett, S., Tepp, W. H., Scherf, J. M., Pier, C. L., & Johnson, E. A. (2015). Activity of botulinum neurotoxin type D (strain 1873) in human neurons. Toxicon : official journal of the International Society on Toxinology, 101, 63–69. https://doi.org/10.1016/j.toxicon.2015.04.015 | ||
Revision as of 18:09, 2 May 2022
Botulinum Neurotoxin
| |||||||||||
References
- ↑ Lakna. (2018, July 16). Difference between spore-forming bacteria and non-spore-forming bacteria. Pediaa.Com. Retrieved April 27, 2022
- ↑ Naumann M, Jankovic J: Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004 Jul;20(7):981-90. doi: 10.1185/030079904125003962. [Article]
- ↑ Patil S, Willett O, Thompkins T, Hermann R, Ramanathan S, Cornett EM, Fox CJ, Kaye AD. Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States. Curr Pain Headache Rep. 2016 Mar;20(3)http://dx.doi.org/10.1007/s11916-016-0545-0
- ↑ 4.0 4.1 4.2 4.3 World Health Organization. (2018, January 10). Botulism. World Health Organization. Retrieved May 2, 2022, from https://www.who.int/news-room/fact-sheets/detail/botulism
- ↑ Mayo Foundation for Medical Education and Research. (2021, September 3). Cervical dystonia. Mayo Clinic. Retrieved April 27, 2022, from https://www.mayoclinic.org/diseases-conditions/cervical-dystonia/symptoms-causes/syc-20354123
- ↑ Oliveira, Ademar Francisco de Filho et al. “Application of botulinum toxin to treat sialorrhea in amyotrophic lateral sclerosis patients: a literature review.” Einstein (Sao Paulo, Brazil) vol. 14,3 (2016): 431-434. doi:10.1590/S1679-45082016RB3594
- ↑ How botox® is injected. The Cosmetic Skin Clinic. (2021, November 2). Retrieved April 27, 2022, from https://www.cosmeticskinclinic.com/advice-centre/how-botox-is-injected
[8]Pellett, S., Tepp, W. H., Scherf, J. M., Pier, C. L., & Johnson, E. A. (2015). Activity of botulinum neurotoxin type D (strain 1873) in human neurons. Toxicon : official journal of the International Society on Toxinology, 101, 63–69. https://doi.org/10.1016/j.toxicon.2015.04.015
[8]Product Monograph: Botox (Clostridium botulinum type A neurotoxin complex ) powder for injectable solution [Link]https://pediaa.com/difference-between-spore-forming-bacteria-and-non-spore-forming-bacteria/
[8]Simpson, L. L., Maksymowych, A. B., & Hao, S. (2001). The role of zinc binding in the biological activity of botulinum toxin. The Journal of biological chemistry, 276(29), 27034–27041. https://doi.org/10.1074/jbc.M102172200 FDA Approved Products: Botox (onabotulinumtoxinA) for injection [Link]
